MedTrace Logo

Immune Dysfunction in Allergic Asthma

NCT00189228 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-09-27

Study results available
· View outcomes & findings →

Summary

We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.

Conditions

Interventions

DRUG

Xolair

Patients are administered Xolair

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of New Mexico

    lead OTHER

Principal Investigators

  • Mark Schuyler, MD · UNM HSC

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189228 on ClinicalTrials.gov